- Home
- PCVX vs CELH Comparison
PCVX vs CELH Comparison
Compare PCVX & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- CELH
- Stock Information
- Founded
- PCVX 2013
- CELH 2004
- Country
- PCVX United States
- CELH United States
- Employees
- PCVX N/A
- CELH N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- PCVX Health Care
- CELH Consumer Staples
- Exchange
- PCVX Nasdaq
- CELH Nasdaq
- Market Cap
- PCVX 4.4B
- CELH 11.7B
- IPO Year
- PCVX 2020
- CELH N/A
- Fundamental
- Price
- PCVX $32.00
- CELH $45.69
- Analyst Decision
- PCVX Strong Buy
- CELH Strong Buy
- Analyst Count
- PCVX 10
- CELH 17
- Target Price
- PCVX $136.50
- CELH $47.24
- AVG Volume (30 Days)
- PCVX 1.5M
- CELH 6.9M
- Earning Date
- PCVX 08-05-2025
- CELH 08-05-2025
- Dividend Yield
- PCVX N/A
- CELH N/A
- EPS Growth
- PCVX N/A
- CELH N/A
- EPS
- PCVX N/A
- CELH 0.32
- Revenue
- PCVX N/A
- CELH $1,329,198,000.00
- Revenue This Year
- PCVX N/A
- CELH $60.22
- Revenue Next Year
- PCVX N/A
- CELH $25.97
- P/E Ratio
- PCVX N/A
- CELH $140.66
- Revenue Growth
- PCVX N/A
- CELH N/A
- 52 Week Low
- PCVX $27.66
- CELH $21.10
- 52 Week High
- PCVX $121.06
- CELH $60.70
- Technical
- Relative Strength Index (RSI)
- PCVX 40.96
- CELH 64.82
- Support Level
- PCVX $32.00
- CELH $45.37
- Resistance Level
- PCVX $34.63
- CELH $46.98
- Average True Range (ATR)
- PCVX 1.35
- CELH 1.54
- MACD
- PCVX -0.09
- CELH -0.01
- Stochastic Oscillator
- PCVX 6.67
- CELH 63.30
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), Celsius On-the-Go powder packets, and the recently acquired portfolio of Alani Nu energy drinks and snacks. Celsius dedicates its efforts to branding and innovation, while it largely utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.